Loss of Endocan tumorigenic properties after alternative splicing of exon 2.

BMC Cancer
F DepontieuPhilippe Lassalle

Abstract

Endocan was originally described as a dermatan sulfate proteoglycan found freely circulating in the blood. Endocan expression confers tumorigenic properties to epithelial cell lines or accelerate the growth of already tumorigenic cells. This molecule is the product of a single gene composed of 3 exons. Previous data showed that endocan mRNA is subject to alternative splicing with possible generation of two protein products. In the present study we identified, and functionally characterized, the alternative spliced product of the endocan gene: the exon 2-deleted endocan, called endocanDelta2. Stable, endocanDelta2-overexpressing cell lines were generated to investigate the biological activities of this new alternatively spliced product of endocan gene. Tumorigenesis was studied by inoculating endocan and endocanDelta2 expressing cell lines subcutaneously in SCID mice. Biochemical properties of endocan and endocanDelta2 were studied after production of recombinant proteins in various cell lines of human and murine origin. Our results showed that the exon 2 deletion impairs synthesis of the glycan chain, known to be involved in the pro-tumoral effect of endocan. EndocanDelta2 did not promote tumor formation by 293 cells implanted ...Continue Reading

References

Jan 1, 1984·Cancer Metastasis Reviews·E A Turley
May 1, 1995·Journal of Leukocyte Biology·R M StrieterS L Kunkel
Aug 23, 1996·The Journal of Biological Chemistry·P LassalleA B Tonnel
Jan 1, 1996·Advances in Cancer Research·N BouckS C Hsu
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Mar 15, 2000·The International Journal of Biochemistry & Cell Biology·S TumovaJ R Couchman
Aug 10, 2000·The Journal of Biological Chemistry·P W ParkM Bernfield
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Sep 8, 2001·Journal of Mammary Gland Biology and Neoplasia·M DeleheddeD G Fernig
Sep 8, 2001·Journal of Mammary Gland Biology and Neoplasia·S J Gendler
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
May 16, 2002·Journal of Vascular Research·Jo C TsaiWilliam C Aird
Jun 6, 2003·Oncogene·Mary J C HendrixRichard E B Seftor
Apr 17, 2004·American Journal of Respiratory and Critical Care Medicine·Alain C BorczukCharles A Powell
Jul 6, 2004·Clinical Biochemistry·Brigitta M N Brinkman
Sep 11, 2004·Cancer Gene Therapy·Gregory M HayesGraeme J Dougherty
Nov 3, 2004·Cancer Research·Julian P Venables
Jan 21, 2006·Critical Care Medicine·Arnaud ScherpereelPhilippe Lassalle
Mar 4, 2006·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 11, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bogdan Dragos GrigoriuPhilippe Lassalle
Mar 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·William T SwaneyEric B Keverne

❮ Previous
Next ❯

Citations

Apr 23, 2013·International Journal of Cell Biology·Maryse DeleheddeRomain R Vivès
Jul 1, 2011·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Patrick PaulusKai Zacharowski
Jul 3, 2015·Biomedical Reports·Jinghui YangXuewen Zhang
Mar 1, 2012·Journal of Immunological Methods·Florence DepontieuPhilippe Lassalle
Dec 12, 2013·Angiology·Thomas F Whayne
Feb 12, 2015·Oncotarget·Arjun KalvalaWenrui Duan

❮ Previous
Next ❯

Datasets Mentioned

BETA
AJ401091
AJ401092
AJ973643

Methods Mentioned

BETA
FCS
enzyme-linked immunosorbent assay
electrophoresis
PCR
immunoprecipitation
xenograft
ELISA
transfection
glycosylation
the

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.